Test Price
2,800 AED✅ Home Collection Available
BRAF Gene Noonan Syndrome Type 7 Genetic Test (NGS) in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين BRAF لمتلازمة نونان النوع السابع بتقنية التسلسل الجيني (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
فحص جيني عالي الدقة بنسبة 99.9% لتشخيص متلازمة نونان النوع السابع المرتبط بطفرات جين BRAF، يُجرى في مختبر معتمد وفق معايير الآيزو مع خدمة سحب منزلي فاخر ونقل مبرد، وتوجيه طبي هاتفي بعد الفحص.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview & Test Utility
The BRAF Gene Noonan Syndrome Type 7 NGS Test detects pathogenic variants in the BRAF gene associated with Noonan syndrome type 7, a multisystem dysmorphology disorder characterized by distinct facial features, congenital heart defects, and developmental delay. This state‑of‑the‑art next‑generation sequencing assay delivers comprehensive coding region analysis from blood, extracted DNA, or FTA card samples, enabling definitive molecular diagnosis and family planning decisions.
| Feature | Our Test (NGS) | Sanger Sequencing (Alternate) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (high‑throughput, full gene coverage) | Single‑gene bidirectional Sanger sequencing |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Variant Detection | SNVs, small indels, copy number variants (with MLPA add‑on if needed) | SNVs and small indels only; CNVs missed |
| Sample Types | Blood, Extracted DNA, FTA Card | Blood only (higher volume) |
| Price (AED) | 2800 | ~4500 |
Physician Insight & Safety Protocol
“A BRAF gene test is a powerful diagnostic tool, but isolated genetic data can mislead without clinical context. I always interpret results alongside dysmorphology findings, echocardiography, and coagulation profiles to avoid false reassurance or unnecessary anxiety. Your child’s care deserves a holistic approach.” — Dr. PRABHAKAR REDDY, DHA License No. 61713011.
⚠ Medication & Clinical Safety Notice
Do not discontinue any prescribed medication (e.g., growth hormone, cardiac drugs, anticoagulants) before or after testing without explicit consultation with your managing physician. This test does not replace cardiology or hematology monitoring.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Unidentified sample, gross hemolysis, sample collected in wrong tube, or patient under 28 days without neonatologist approval.
- Red Flags (seek immediate care): New onset severe cyanosis, syncope, bleeding diathesis (easy bruising, mucosal bleeding), or acute neurological changes – these may indicate evolving complications of Noonan syndrome and require urgent cardiology/hematology evaluation.
Frequently Asked Questions & Clinical Guidance
1. What is the diagnostic accuracy of this BRAF Noonan syndrome test?
This NGS assay achieves >99.9% analytical sensitivity and specificity for BRAF coding variants, confirmed by orthogonal confirmation of pathogenic findings; clinical sensitivity for Noonan syndrome type 7 is near 100% when typical features are present.
2. ما هي أهمية فحص جين BRAF في تشخيص متلازمة نونان؟
يؤكد فحص التسلسل الجيني (NGS) وجود طفرات في جين BRAF المسؤولة عن النوع السابع من متلازمة نونان، مما يتيح التشخيص الدقيق والمراقبة الطبية الموجهة للقلب والنمو والتخثر.
3. How should I prepare my child for the blood draw or FTA card collection?
No fasting or medication changes are required; simply ensure the child is well‑hydrated and calm. Our paediatric‑trained phlebotomist will use a butterfly needle for minimal discomfort, and the FTA card option requires only a finger‑prick drop.
Regulatory & Quality Assurance
- Federal Decree‑Law No. 41 of 2024 (Art. 87): This genetic test is offered only after documented pre‑ genetic counselling and informed consent, in compliance with UAE genomic data protection mandates.
- CDS Law 2026 (Minors): For children below 18, consent is obtained from the legal guardian, and results are communicated exclusively through the referring paediatrician/clinical geneticist.
- UAE PDPL: All genomic data is encrypted, stored on UAE‑based servers, and never shared without explicit bi‑directional consent.
- ISO 9001:2015 Certification INT/EGQ/2509DA/3139 – ensuring end‑to‑end quality from sample accessioning to reporting.
- Facility License: 9834453 (DHA/MOHAP).
- ICD‑10‑CM 2026: Q87.1 (Noonan syndrome), Z13.79 (screening for genetic anomalies), Z82.79 (family history of congenital malformations) – including susceptibility marker BRAF c.770A>G and related variants.
- LOINC: 79328-3 – BRAF gene mutations found in Blood or Tissue by Sequencing.
- Methodology: Next‑Generation Sequencing (Illumina platform, 100x mean coverage) with bioinformatic analysis using ClinVar, HGMD, and ACMG 2026 guidelines.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians